No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer

byBryan Sun

August 18, 2023

in StudyGraphics

Reading Time: 1 min read

Click to read the study in The Lancet

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Increasing cancer incidence rates in younger and older adults worldwide

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

Tags: prostate cancer talazoparib

Delivery at 39 weeks is recommended for pregnancies conceived via infertility treatments and assisted reproductive technology

RelatedReports

Population-based risk factors and geographical trends identified for vitiligo

Oncology

Increasing cancer incidence rates in younger and older adults worldwide

October 20, 2025

Radiation plus hormone therapy may improve prostate cancer survival

Chronic Disease

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

August 14, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025

The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025

Decline in adolescent sleep duration over past 20 years

Long sleep duration may be associated with carotid plaque burden

Age and number of islet autoantibodies associated with diabetes risk

Nemolizumab Therapy for Moderate-to-Severe Prurigo Nodularis

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE)

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result